{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016275","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.406048+00:00","generated_at":"2026-06-02T02:08:45.815685+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Zevra Therapeutics shareholders reject amendments to 2014 Equity Incentive Plan at annual meeting","bullets":["Three Class III directors elected: Thomas D. Anderson, Neil F. McFarlane, Alvin Shih, M.D.","Shareholders ratified Ernst & Young LLP as independent auditor for FY2024.","Advisory say-on-pay vote approved (11.2M for, 9.9M against).","Proposal to amend 2014 Equity Incentive Plan failed: 4.1M for, 17.0M against, 9.9M broker non-votes.","Approximately 74.5% of shares represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016275","json":"https://secwatch.observer/filing/0001437749-24-016275.json","markdown":"https://secwatch.observer/filing/0001437749-24-016275.md","text":"https://secwatch.observer/filing/0001437749-24-016275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/zvra20240513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:08:45.815685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03367ac9e2a3ce227c223ac2713dddb8a4100208","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Election of Alvin Shih, M.D. as a Class III director at the 2024-05-13 meeting.","evidence_excerpt":"Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}],"fact_type":"shareholder_vote"},{"claim_id":"0688704839e806eb896998afe648a5a5584a569a","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Election of Neil F. McFarlane as a Class III director at the 2024-05-13 meeting.","evidence_excerpt":"Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}],"fact_type":"shareholder_vote"},{"claim_id":"90eaecd0f1d33122eef4b4ce3827f95f4d0a0a61","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Election of Thomas D. Anderson as a Class III director at the 2024-05-13 meeting.","evidence_excerpt":"1. Election of Directors For Withheld Broker Non-Votes Thomas D. Anderson 15,266,761 6,062,268 9,865,186","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}],"fact_type":"shareholder_vote"},{"claim_id":"a8c3b60819fa0f0cc0345690da1789ff8d6e4d85","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Advisory approval of compensation of named executive officers at the 2024-05-13 meeting.","evidence_excerpt":"3. Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers. 11,167,215 9,888,153 273,661 9,865,186","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}],"fact_type":"shareholder_vote"},{"claim_id":"aaa5f185fe0f9cb6b081f0fa03dc331f18594538","claim":"ZEVRA THERAPEUTICS, INC. shareholders rejected Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan at the 2024-05-13 meeting.","evidence_excerpt":"4. Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan 4,143,728 16,964,060 221,241 9,865,186","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2024-05-13"}],"fact_type":"shareholder_vote"},{"claim_id":"e956bde1306003b12c66b6fe9b6eaec090cd09e5","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-13 meeting.","evidence_excerpt":"2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company ’ s fiscal year ending December 31, 2024. 22,543,306 7,352,086 1,298,823 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}